Duearity

EN Texto em inglês Ainda não há artigo no teu idioma: trecho em inglês.

Duearity was a Swedish medical technology company based in Malmö. The company specialised in hardware and software for tinnitus treatment. From May 2021 to September 2024, Duearity was publicly traded on the Nasdaq First North stock exchange. Peter Arndt, one of Duearity's founders, was undergoing tinnitus retraining therapy (TRT) and noticed the treatment to be effective, but incompatible with daily life. Tinnitus retraining therapy is based on cognitive behavioral therapy and requires white noise to be played uninterrupted for 6-8 hours per day for 6-24 months. Wearing headphones for prolonged and uninterrupted period of time was interfering with work during daytime and with sleep during nighttime. The founders set out to find a solution that did not require headphones and did not occupy the ear canals. In 2020, a proof of concept was successfully completed and the company applied for a patent. On 11 May 2021, the company's shares debuted on Nasdaq First North under ticker symbol DEAR. The company was previously called Cochlearity, but the name was changed pre-IPO in order to avoid mixup with another medtech company.